-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CxBcqrmlPQfQqmR76j7cL2AgL3O9OGGOt8+c2KA68QkkamEaWqdGcDekKyg7BpRz mrJO0EGFIy88j0BPUO8n8w== 0001144204-10-052183.txt : 20101004 0001144204-10-052183.hdr.sgml : 20101004 20101004135947 ACCESSION NUMBER: 0001144204-10-052183 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20101004 ITEM INFORMATION: Other Events FILED AS OF DATE: 20101004 DATE AS OF CHANGE: 20101004 FILER: COMPANY DATA: COMPANY CONFORMED NAME: APRICUS BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001017491 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870449967 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-22245 FILM NUMBER: 101105013 BUSINESS ADDRESS: STREET 1: 6330 NANCY RIDGE DRIVE, STREET 2: SUITE 103 CITY: SAN DIEGO, STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 222-8041 MAIL ADDRESS: STREET 1: 6330 NANCY RIDGE DRIVE, STREET 2: SUITE 103 CITY: SAN DIEGO, STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: NEXMED INC DATE OF NAME CHANGE: 19970311 8-K 1 v198180_8k.htm 8-K
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 4, 2010

Apricus Biosciences, Inc.
(Exact name of registrant as specified in its charter)

Nevada
0-22245
87-0449967
(State or other jurisdiction of
incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
     
6330 Nancy Ridge Drive, Suite 103, San Diego, California
92121
(Address of principal executive offices)
(Zip Code)

Registrant’s telephone number, including area code  (858) 222-8041
 

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))

 
 
 

Item 8.01
Other Events.

On October 4, 2010, Apricus Biosciences, Inc. completed a best-efforts offering (the “Offering”) for the sale of 1,728,882 Units, with each Unit consisting of three shares of common stock, par value $0.001 per share, and a warrant to purchase one additional share of common stock.  The Units were offered to the public at a price of $5.40 and the warrants, which are exercisable starting at the closing and remaining exercisable thereafter for a period of five years, have an exercise price of $2.27 per share.  The Company received Offering proceeds, net of discounts, commissions and expenses, of approximately $8,340,000.  The Company will use the net proceeds from the Offering to further develop its product candidates and for working capital and other general corporate purposes, as more fully described in the Offering prospectus.

The Offering was made pursuant to the Company’s effective registration statement on Form S-1 (File No. 333-169132).  Dawson James Securities, Inc. acted as the Company’s placement agent for the Offering.

*           *           *
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Apricus Biosciences, Inc.
     
 
By:
/s/ Mark Westgate
   
Name: Mark Westgate
   
Title: Vice President and Chief Financial Officer
 
Date: October 4, 2010

 
 
 
  -----END PRIVACY-ENHANCED MESSAGE-----